Brought to you by:
Mechanical thrombectomy system for AV access shows promise, study shows
A retrospective analysis of 64 patients treated between 2022 and 2025 using a novel mechanical thrombectomy system to treat dialysis access thrombus showed function was restored in 91% of those treated. Data from the study of the InThrill system (Stryker/…
STORM-PE finds mechanical thrombectomy superior to anticoagulation alone
The use of mechanical thrombectomy, specifically computer-assisted vacuum thrombectomy (CAVT) using the 16Fr Lightning Flash system (Penumbra), with anticoagulation achieves superior reduction in right heart strain compared to anticoagulation therapy alone in patients with acute intermediate-high-risk pulmonary embolism (PE). This…
SVS Foundation set to launch Enrico Ascher Vascular Innovation Institute at VAM 2026
The Society for Vascular Surgery (SVS) Foundation will formally establish the Enrico Ascher Vascular Innovation Institute as a new entity under its research and innovation portfolio, following generous support from the Ascher family. Set to launch at the 2026 Vascular…
Closer to the goal: Shoring up data behind breakthrough imaging technology that plots a radiation-free future in new RCT
UMass chief peers down the lens of an if-not radiation-free complex aortic procedural future, then one in which the methods of today will look positively quaint. “I say this a lot,” says Andres Schanzer, MD, “but I think there is…
A global concern: WFVS seeks to level up vascular education in every corner of the world
WFVS secretary general details how the organization has evolved in recent years, seeing gains in representation and access to education among members from underserved regions. In the stew of national and regional vascular societies that dot the globe, the World…
Shape Memory Medical announces midway milestone in AAA-SHAPE randomised controlled pivotal trial
Shape Memory Medical has reached 50 per cent enrolment in its ongoing AAA-SHAPE pivotal trial, the company announced last week. AAA-SHAPE is a prospective, multicenter, randomized, open-label trial to determine safety and effectiveness of the Impede-FX RapidFill device to improve…
Randomized trial finds inferior mesenteric artery embolization ‘may not be effective’ in EVAR
Results from a multicenter randomized controlled trial (RCT) indicate that pre-emptive inferior mesenteric artery (IMA) embolisation during endovascular aneurysm repair (EVAR) does not significantly reduce aneurysm sac volume or rates of type II endoleak. The CLARIFY IMA study—which the authors…
Medtronic’s Endurant receives FDA labelling approval to remove rAAA treatment warning
Medtronic recently announced it has received Food and Drug Administration (FDA) labelling approval for the Endurant stent graft system, by adding ruptured abdominal aortic aneurysm (rAAA) clinical evidence and removing the rAAA treatment warning. A press release notes that this…
EACTS 2025 hears new data on aortic arch remodelling device
Data from the AMDS PERSEVERE and PROTECT trials—both assessing the use of the Ascyrus medical dissection stent (AMDS, Artivion)—were presented in late-breaking science presentations at the 39th European Association for Cardio-Thoracic Surgery (EACTS) annual meeting (8–11 October, Copenhagen, Denmark). The…
Nurea receives US FDA clearance for AI-powered PRAEVAorta 2 software
Nurea’s PRAEVAorta 2 artificial intelligence (AI)-powered software has received US Food and Drug Administration (FDA) 510(k) clearance, a company press release reveals. According to Nurea, PRAEVAorta 2 provides vascular physicians with advanced automated measurement tools for aortic diameters on contrasted…